One of the most devastating diseases finally has a treatment that can slow its progression and transform lives, tearful ...

The FDA is said to be making a U-turn on uniQure’s one-time gene therapy candidate for Huntington’s disease despite the ...

The path to approval for uniQure’s gene therapy candidate for Huntington’s disease is in doubt as the US Food and Drug Administration (FDA) has brought into question the adequacy of the company's ...

In a major setback, Uniqure said that the timing of when it can file its Huntington's treatment for FDA approval "is now unclear." ...

UniQure stock crashed Monday on "confusing" and "unexpected" feedback from the FDA for its Huntington's disease gene therapy.

LEXINGTON, Mass. and AMSTERDAM, Nov. 03, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing ...

However, in late September 2025, scientists successfully treated Huntington’s for the first time in a ground-breaking study.

An experimental gene therapy slowed Huntington’s by up to 75 percent in a small clinical trial. While not a cure, it may give patients longer lives.

Families are elated by news of the first treatment for Huntington's disease - but when and how will the NHS fund it?

A woman whose mother, aunt and grandmother died from Huntington's disease has described a breakthrough in treating the ...

The United States Huntington's Disease Treatment Market is set to expand significantly, with an expected CAGR of 15.22% from ...

AMT-130, aimed at treating Huntington’s disease (HD). This article will delve into the recent feedback from the U.S. Food and Drug Administration (FDA), the implications for the therapy's regulatory ...